U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06865885) titled 'LDL-C Optimization Using Inclisiran in Patients in Which Drug-Drug Interactions Limit LDL Lowering' on March 04.
Brief Summary: Drug-drug interactions often limit statin optimization in a population of patients prescribed cytochrome P3A4 inhibitors, which include immunosuppressive agents, protease inhibitors, and antifungals. Unfortunately, these patients often have autoimmune conditions or rheumatologic disorders that are being treated by these complex drug regimens and are often on low-dose statin or no statin at all with suboptimal LDL levels despite their increased cardiovascular (CV) risk. There is an unmet clinical need to im...